This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Cambrex And Tillotts Enter A Development And Commercialization Agreement For Proprietary 5-ASA-Based Technology

EAST RUTHERFORD, N.J. and RHEINFELDEN, Switzerland, July 6, 2011 /PRNewswire/ -- Cambrex Corporation (NYSE: CBM, "Cambrex") and Tillotts Pharma AG ("Tillotts") are pleased to announce they have entered into a Development and Commercialization Agreement for a proprietary mesalamine-based (5-ASA) technology for use in the treatment of Inflammatory Bowel Disease (IBD).  

"This deal, which gives Tillotts worldwide access to an exciting proprietary 5-ASA-based technology, is an additional important step in our forceful efforts over the years to come to build an attractive and innovative gastrointestinal product portfolio, complementary to our Asacol® and Colpermin®," commented Thomas A. Toth von Kisker, President and CEO of Tillotts.

Steven M. Klosk, President and CEO of Cambrex added, "Today's announcement serves as a prime example of Cambrex's commitment to accelerating our customers' drug development processes by providing technology-added products and services and further underscores our goal to being a leading player in the development and supply of mesalamine-based active ingredients."

Under the terms of the agreement, Tillotts has acquired from Cambrex worldwide exclusive rights to develop and commercialize drug products based on the proprietary 5-ASA-based technology in exchange for developmental, regulatory and IP milestone payments as well as royalties. Cambrex previously acquired the exclusive rights to this technology from PLx Pharma Inc. ( Houston, TX).

About Tillotts

Tillotts is a speciality pharma company with a leading position in the field of gastroenterology with its headquarters in Rheinfelden, Switzerland. It is a subsidiary of Zeria Pharmaceutical Co., Ltd., ( www.zeria.co.jp) a company publicly traded on the Tokyo stock exchange. Tillotts specializes in the development and commercialization of pharmaceutical products, diagnostics as well as medical devices all in the field of gastroenterology. For more information, please visit www.tillotts.com.    

About Cambrex

Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. We offer Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. For more information, please visit www.cambrex.com.  

Tillotts' trade marks Asacol®, Octasa®, Asacolon®, Colpermin®, Topasa® and Xenema® are either registered or applied for in up to 70 countries. The trade mark Asacol® is a registered trade mark by Warner Chilcott in the United States of America, Canada and the United Kingdom. Asacol® is a registered trade mark in Italy by Giuliani and in Switzerland by Sanofi-Aventis. In the Benelux the trade mark is registered by Nycomed. Colpermin® is a registered trade mark by Johnson & Johnson for the United Kingdom and Ireland.

SOURCE Cambrex Corporation; Tillotts Pharma AG

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,106.04 +19.41 0.11%
S&P 500 1,990.52 +3.51 0.18%
NASDAQ 4,480.5230 +6.8260 0.15%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs